Stock LO3A LONZA GROUP AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Lonza Group AG Deutsche Boerse AG

Equities

LO3A

US54338V1017

Market Closed - Deutsche Boerse AG
Other stock markets
 07:05:42 27/06/2024 BST 		5-day change 1st Jan Change
50.5 EUR 0.00% Intraday chart for Lonza Group AG +1.41% +35.75%
06-20 Berenberg Lifts Price Target on Lonza Group, Maintains Buy Recommendation MT
05-14 Swiss Market Index Edges Up Ahead of Inflation Report MT

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.55 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
LONZA GROUP AG Stock Lonza Group AG
+35.75% 39.08B -
MODERNA, INC. Stock Moderna, Inc.
+21.85% 46.93B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.48B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.04% 31.01B
B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.65% 25.88B
B-
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+38.43% 12.53B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.92% 11.36B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.29% 10.65B
C+
QIAGEN N.V. Stock Qiagen N.V.
-8.20% 9.04B
A
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LONN Stock
  4. LO3A Stock
  5. Ratings Lonza Group AG